---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-187257"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:13:12.131541+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aeglea BioTherapeutics transfers listing to Nasdaq Capital Market to address bid price deficiency

## Summary
- Received notice of Minimum Bid Price non-compliance on Jan 13, 2023; initial grace period ended July 12, 2023.
- Nasdaq approved transfer to Capital Market effective July 14, 2023; stock symbol remains AGLE.
- Granted additional 180-day grace period until Jan 8, 2024 to regain $1.00 bid price for 10 consecutive days.
- Company intends to implement reverse stock split (approved by stockholders on June 6, 2023) to regain compliance.
- Failure to regain compliance by Jan 8, 2024 could result in delisting; may appeal to Nasdaq Hearings Panel.

## SEC filing metadata
- accession: 0001193125-23-187257
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523187257/0001193125-23-187257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523187257/d489147d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-187257
- JSON: https://secwatch.observer/filing/0001193125-23-187257.json
- Plain text: https://secwatch.observer/filing/0001193125-23-187257.txt

## Key facts
- Listing & Compliance Notices
  Spyre Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: July 13, 2023, the Company received approval from Nasdaq of the Transfer (the “Approval”). The Transfer became effective at the opening of business on July 14, 2023. The Company’s Common Stock continues to trade under the symbol “AGLE.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. In connection with the Approval, the Company has been granted an additional 180-calendar day
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523187257/0001193125-23-187257-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.